Arrowhead Pharmaceuticals, Inc. (0HI3.L)

24,03 -0,76 (-3,07%) Börsenschluss: 06:34PM BST

Arrowhead Pharmaceuticals, Inc.

177 East Colorado Boulevard
Suite 700
Pasadena, CA 91105
United States
626 304 3400
https://arrowheadpharma.com

Sektor(en): 
Branche: 
Vollzeitmitarbeiter: 525

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Christopher R. Anzalone Ph.D.	CEO, President & Director	1,6M	5,26M	1969
Mr. Kenneth A. Myszkowski	Chief Financial Officer	834,34k	N/A	1966
Mr. Patrick O'Brien J.D., PharmD	COO, General Counsel & Secretary	835,14k	990,4k	1964
Dr. James C. Hamilton M.D., MBA	Chief of Discovery & Translational Medicine	762,14k	N/A	1978
Dr. Mark M. Davis Ph.D.	Founder and Founder & Director of Insert Therapeutics Inc & Calando	N/A	N/A	N/A
Dr. Vincent Anzalone CFA	Head of Investor Relations & VP	N/A	N/A	N/A
Mr. Howard Lovy	Director of Communications	N/A	N/A	N/A
Dr. Bruce D. Given M.D.	Chief Medical Scientist	486,31k	5,93M	1954
Dr. Mark Seefeld	Head of Toxicology & VP	N/A	N/A	1954
Ms. Tracie Oliver	Chief Commercial Officer	449,58k	N/A	1962

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Corporate Governance

Arrowhead Pharmaceuticals, Inc.s ISS Governance QualityScore, Stand 1. April 2024, lautet 4. Die grundlegenden Scores sind Audit: 9, Vorstand: 7, Shareholderrechte: 1, Kompensation: 2.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.